Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $239
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $231 to $239.
Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $231 to $239.